Uncategorized
Aerie Pharmaceuticals Enters into Collaboration Agreement with DSM Focused on Technology to Potentially Deliver Aerie Compounds to Treat Retinal Diseases such as Wet AMD
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has entered into a collaborative research, development and license agreement with DSM. The research collaboration agreement includes an option to license DSM’s bioerodible polymer implant technolo